<p>Ziprasidone is indicated for the treatment of&nbsp;schizophrenia, as monotherapy for the acute treatment of bipolar&nbsp;manic&nbsp;or mixed episodes, and as an adjunct to&nbsp;lithium&nbsp;or valproate for the maintenance treatment of bipolar disorder. Ziprasidone&nbsp;intramuscular&nbsp;is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone&#39;s greater capacity to prolong the QT/QTc interval compared to several other&nbsp;antipsychotic&nbsp;drugs. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type&nbsp;arrhythmia, a potentially fatal&nbsp;polymorphic&nbsp;ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known.</p>